Prevention & care

Thyroid cancer: nodules, cell families, hormone tests, radioactive iodine, and screening

9 sources · Latest source check 2026-10-08 UTC

On this page

Thyroid cancer is a malignant growth in the gland at the lower front of the neck. The thyroid contains hormone-producing follicular cells and calcitonin-producing C cells. Cancers arising from these different cells are not one disease with one treatment or outlook.[1]

The tissue family changes the meaning of a diagnosis

The tissue family changes the meaning of a diagnosis
Family	Main distinction
Differentiated	Includes papillary, follicular and oncocytic cancers.[1]
Medullary	Arises from C cells; sporadic and inherited forms occur.[1]
Anaplastic	An undifferentiated, often rapidly growing family.[1]
Other tumors	Thyroid lymphoma and nearby parathyroid cancer need separate classification.[1]

Nodule describes a finding, not its tissue diagnosis

A nodule is a lump of thyroid cells. ACS describes fluid-filled and solid nodules and notes that most are not cancer. Goiter describes gland enlargement. Neither a solid appearance nor a generic “thyroid problem” label establishes a malignant cell family.[1]

TSH measures function rather than proving a nodule benign

ATA explains that thyroid function tests can be normal even when a nodule contains cancer. Hormone production and tissue malignancy answer different questions. Normal TSH is therefore not a substitute for the assessment appropriate to an identified nodule.[2]

A growing neck lump and persistent voice change need assessment

NHS describes a new or enlarging neck lump, persistent hoarseness and pressure symptoms. Similar symptoms have many other causes. Difficulty swallowing or breathing warrants urgent help; an urgent referral means investigation is needed, not that cancer has already been diagnosed. The inspected page was reviewed in May 2023.[3]

Ultrasound, needle sampling and surgical pathology have different roles

NHS describes ultrasound to examine the gland and fine-needle sampling to inspect cells. Some findings need further investigation or operative tissue assessment. Not everyone needs every test. Ask whether the current result is conclusive, uncertain or insufficient, and what the next test could resolve.[4]

A papillary variant is not the same as follicular cancer

ACS distinguishes the follicular variant of papillary cancer from follicular thyroid cancer and notes that variants can behave differently. A word in a subtype name cannot substitute for the complete pathology report. Stage describes extent; tissue family describes what the cancer is.[1]

Age contributes to staging in some thyroid families

NCI describes different papillary and follicular staging groups below age 55 and at age 55 or older. Age contributes within that framework; this page does not assign a personal stage.[5]

An inherited RET variant and a tumor finding are different settings

NCI describes inherited RET changes in some medullary cancers and assessment of relatives. An inherited-risk result differs from tumor sequencing; ask what the finding and counseling concern.[5]

Lobectomy and total thyroidectomy remove different amounts of tissue

NHS distinguishes removal of part of the gland from removal of the whole gland. The appropriate operation depends on the cancer and broader health. Ask about voice, swallowing, calcium-related complications, recovery and hormone needs before consenting; an operation name alone does not convey its benefits and harms.[6]

Replacement and TSH suppression serve different purposes

After treatment, thyroid hormone tablets can replace hormone the gland can no longer make. In selected cancer settings, hormone treatment also aims to reduce TSH stimulation. NCI explains these separate goals. The monitoring target and possible adverse effects should be discussed with the treating team rather than inferred from a tablet’s name.[5]

Radioactive iodine is a particular treatment, not nutritional iodine

NCI describes oral radioactive iodine for selected papillary or follicular cancers and explicitly states that it is not used for medullary cancer. A nutritional iodine supplement is not radioactive-iodine therapy. Uptake by the relevant cancer tissue matters; the same organ location does not establish the same treatment suitability.[5]

Targeting thyroid tissue does not mean an absence of other harms

ATA describes treatment-related dry mouth, dry eyes and taste changes, along with concerns about later secondary cancers. Radiation precautions and pregnancy or breastfeeding restrictions need clinical planning. Preparation, hormone adjustment and contact precautions should come from the treating service; this page provides no self-treatment schedule.[7]

Non-inferiority has a margin and a population

IoN used a five-percentage-point non-inferiority margin. The authors’ omission conclusion concerns pT1/pT2, N0/Nx tumors without adverse features; the study continued follow-up and was funded by Cancer Research UK. It does not establish lifelong equivalence or support omitting treatment for every thyroid family or risk category.[8]

Finding more small cancers does not itself prove screening saves lives

USPSTF’s May 2017 statement identifies overdiagnosis and overtreatment among screening harms. It applies to general asymptomatic adults, excluding symptoms and specified higher-risk histories. This older recommendation should not be confused with a newly completed 2026 review or a reason to dismiss a new lump.[9]

Follow-up should explain recurrence checks and treatment effects

NHS describes regular checks and contact with the specialist team between appointments. Useful questions include why a test is being repeated, what result would change care, and who handles voice, swallowing or hormone problems. The inspected May 2023 page does not provide a complete current ranking of advanced-cancer medicines.[6]

Evidence & uncertainty

The inspected US recommendation advises against general asymptomatic thyroid screening. It excludes symptom assessment and specified higher-risk settings. Investigation of a lump has a different purpose; an older screening statement does not settle every diagnostic question.[9]

Selected-source overview · Independent review pending

Published questions

Are medullary and papillary thyroid cancers the same cell family?

Selected-source overview · Independent review pending. Read the evidence context.

Medullary cancer arises from C cells; papillary cancer belongs to the differentiated follicular-cell family.[1]

Evidence behind this answer

What Is Thyroid Cancer?
professional association explanation · Date not stated
Selected relevant original official page passages inspected · Follicular cells, C cells, differentiated subtypes and other tissue families